Drugs / γδ T-PD-1 Ab cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07172178 | Oct 2025 → Oct 2028 expected | meningioma | Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06404281 | Aug 2024 → Jan 2026 overdue | neoplasm | Changzhou No.2 People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | γδ T-PD-1 Ab cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06404281 ↗ |
| Modality | Cell therapy | “ex-vivo expanded γδ T-PD-1 Ab cells” NCT07172178 ↗ |
| Route | Other | “The ex-vivo expanded γδ T-PD-1 Ab cells will be adoptively transfused to tumor patients.” NCT06404281 ↗ |